FDA approved veligrotug-vvze for TED regardless of activity or duration, using a 12-week course of five IV infusions administered every three weeks. Pivotal THRIVE/THRIVE-2 trials met primary and all ...
This segment brings together two essential threads — the broader context of lorlatinib's remarkable durability relative to ...
Kutscher says MDVIP is expanding into specialty care and eyeing pediatrics. Your browser does not support the audio element.
This segment addresses one of the most practically important aspects of lorlatinib therapy — its distinct and manageable ...
Thomas Martens, M.D., explains what drives adoption and how CONNECT's Level A evidence could move CGM coverage. New evidence ...
Positive symptoms correlated with more negative sentiment and longer utterances, whereas negative symptoms aligned with ...
Hofstra University and Northwell Health’s jointly founded medical school has secured funding from the National Institutes of ...
Skinvive by Juvéderm recently received FDA approval as the first hyaluronic acid injectable indicated for reducing horizontal ...
The healthcare industry succeeded in making behavioral healthcare more accessible, argues Machinify's Lisa Pincher. Now, it must build the infrastructure to support that care responsibly. What happens ...
Lung cancer has shifted from a rare, smoking-driven disease to one increasingly seen in young non-smokers, especially women, with possible links to pesticide exposure from otherwise “healthy” diets.
Include a simple, one-sentence biography that includes the author’s name, their graduate-level degrees, title, primary affiliation and location of the primary affiliation, e.g., Jill Jones, M.D., MBA, ...
Tom Kraus, J.D., is chief advocacy officer and vice president of government relations at ASHP (American Society of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results